First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors

被引：2
|
作者：
Cooper, A. [1 ]
Andelkovic, V. [2 ]
Wilkinson, K. [1 ]
Ganju, V. [3 ]
Lundy, J. [3 ]
Hong, M. [1 ]
Airey, S. [2 ]
Meng, L. L. [4 ]
Shen, B. [5 ]
Li, H. [6 ]
Yao, L. [7 ]
Zhang, M. [3 ,8 ]
Coward, J. [2 ]
机构：
[1] Liverpool Hosp, Dept Med Oncol, South Western Sydney Local Hlth Dist, Liverpool, NSW, Australia
[2] ICON Canc Ctr South Brisbane, Dept Gynaeoncol, Brisbane, Qld, Australia
[3] Peninsula & Southeast Oncol, Dept Oncol, Frankston, Vic, Australia
[4] Abbisko Therapeut Co Ltd, Med Clin, Shanghai, Peoples R China
[5] Abbisko Therapeut Co Ltd, Translat Med, Shanghai, Peoples R China
[6] Abbisko Therapeut Co Ltd, Biometr, Shanghai, Peoples R China
[7] Abbisko Therapeut Co Ltd, Clin Pharmacol, Shanghai, Peoples R China
[8] Abbisko Therapeut Co Ltd, Clin Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1886
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
700P
引用
收藏
页码：S487 / S487
页数：1
相关论文
共 50 条
  • [21] CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
    Sanborn, Rachel E.
    Hamid, Omid
    de Vries, Elisabeth Ge
    Ott, Patrick A.
    Garcia-Corbacho, Javier
    Boni, Valentina
    Bendell, Johanna
    Autio, Karen A.
    Cho, Daniel C.
    Plummer, Ruth
    Stroh, Mark
    Lu, Lawrence
    Thistlethwaite, Fiona
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
  • [22] First-in-human study of TAS-115, a novel oral MET/VEGFR inhibitor, in patients with advanced solid tumors.
    Matsubara, Nobuaki
    Shitara, Kohei
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ohno, Izumi
    Takahashi, Hideaki
    Bando, Hideaki
    Kojima, Takashi
    Fuse, Nozomu
    Yamazaki, Tomoko
    Hirayama, Naoki
    Fujita, Hidenori
    Nishida, Toshirou
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] A phase 1 study of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors: Updated safety, efficacy, and pharmacokinetics (PK) results
    Prenen, Hans
    Daniel, Jeannie
    Ebiana, Victoria
    Howe, Jason
    Gong, Xiaohua
    Spitz, Susan
    Italiano, Antoine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] A FIRST-IN-HUMAN STUDY OF INTRAVENOUS BAL 101553, A NOVEL MICROTUBULE INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS
    Molife, L. Rhoda
    King, J.
    Smith, A.
    D'arcangelo, M.
    Brown, N.
    Diamantis, N.
    Lane, H.
    Hoffmann, A. H. Schmitt
    Engelhardt, M.
    Plummer, R.
    Kristeleit, R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [25] First-in-human dose-escalating trial of E. coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.
    Chung, Thomas Kenwise
    Rosenthal, Eben
    Parker, William B.
    Allan, Paula
    Clemons, Lisa
    Lowman, Deborah
    Hong, Jeong
    Hunt, Frank R.
    Richman, Joshua
    Conry, Robert Martin
    Mannion, Kyle
    Carroll, William
    Nabell, Lisle
    Sorscher, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumors
    Hong, David S.
    Rosen, Peter J.
    Lockhart, A. Craig
    Fu, Siqing
    Janku, Filip
    Kurzrock, Razelle
    Khan, Rabia
    Amore, Benny
    Caudillo, Isaac
    Deng, Hongjie
    Hwang, Yuying C.
    Loberg, Robert D.
    Shubhakar, Poornima
    Zoog, Stephen
    Beaupre, Darrin M.
    Lee, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [27] CHIR-258: first-in-human phase 1 dose escalating trial of an oral, selectively targeted tyrosine kinase inhibitor in patients with solid tumors.
    Sarker, D
    Evans, J
    Judson, I
    Butzberger, P
    Marriott, C
    Morrison, R
    Vora, J
    Heise, C
    Hannah, A
    de Bono, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 202S - 202S
  • [28] First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
    Hamilton, Erika P.
    Wang, Judy S.
    Oza, Amit M.
    Patel, Manish R.
    Ulahannan, Susanna V.
    Bauer, Todd
    Karlix, Janet L.
    Zeron-Medina, Jorge
    Fabbri, Giulia
    Marco-Casanova, Paola
    Moorthy, Ganesh
    Hattersley, Maureen M.
    Littlewood, Gillian M.
    Mitchell, Patrick
    Saeh, Jamal
    Pouliot, Gayle P.
    Moore, Kathleen N.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (10) : 1154 - 1165
  • [29] First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.
    Hong, Yong Sang
    Lee, Jeeyun
    Han, Hye Sook
    Lee, Soo Jung
    Kim, Jin-Soo
    Ryoo, Baek-Yeol
    Lim, Hyeong-Seok
    Lee, Dae Ho
    Kim, Kyu-Pyo
    Kim, Jeong Eun
    Park, Se Hoon
    Kim, Seung Tae
    Lee, Ki Hyeong
    Choi, Moon Ki
    Han, Hyesun
    Noh, Young Su
    Kim, Yo Han
    Kang, Jahoon
    Son, Jeewoong
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] First-in-human phase 1 study of E7090, a novel selective inhibitor of FGFRs, in patients with advanced solid tumors
    Koyama, Takafumi
    Shimizu, Toshio
    Iwasa, Satoru
    Fujiwara, Yutaka
    Kondo, Shunsuke
    Kitano, Shigehisa
    Yonemori, Kan
    Shimomura, Akihiko
    Iizumi, Sakura
    Sasaki, Tatsuya
    Furuse, Junji
    Yamamoto, Noboru
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12345